Axsome Therapeutics, Inc.
AXSM
Rang in aandelen
#2361
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Aandeelprijs
$159.65
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$8.36B
Verandering (1 dag)
2.46%
Verandering (1 jaar)
21.51%
Land
US
Handel Axsome Therapeutics, Inc. (AXSM)
Categorie
Healthcare
Winst voor Axsome Therapeutics, Inc. (AXSM)
Winst in Jun 2026 TTM: $-191.09M
Volgens de meest recente financiële verslagen van Axsome Therapeutics, Inc. bedraagt de huidige winst van het bedrijf $-191.09M. In 2023 behaalde het bedrijf een winst van $-238.28M, een daling ten opzichte van de winst van 2022, die $-187.13M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Axsome Therapeutics, Inc. van 2013 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-191.09M | -33.45% |
| 2024 | $-287.13M | 20.50% |
| 2023 | $-238.28M | 27.33% |
| 2022 | $-187.13M | 43.50% |
| 2021 | $-130.40M | 26.73% |
| 2020 | $-102.90M | 50.56% |
| 2019 | $-68.35M | 120.71% |
| 2018 | $-30.97M | 6.99% |
| 2017 | $-28.94M | 6.40% |
| 2016 | $-27.20M | 157.60% |
| 2015 | $-10.56M | 75.98% |
| 2014 | $-6.00M | 176.95% |
| 2013 | $-2.17M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -2,860.48% |
US
|
|
| $-3.09B | 1,515.50% |
US
|
|
| $-4.02B | 2,001.77% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,120.82% |
NL
|
